BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson KB, Campbell EJ, Chi H, Zheng H, King LY, Wu Y, Delemos A, Hurairah A, Corey K, Richter JM. Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci. 2014;59:174-182. [PMID: 23990035 DOI: 10.1007/s10620-013-2832-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Jafri SM, Gordon SC. The consequences of cirrhosis in America. Dig Dis Sci 2015;60:283-4. [PMID: 25399328 DOI: 10.1007/s10620-014-3425-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Gaspar R, Castelo Branco C, Macedo G. Liver and COVID-19: From care of patients with liver diseases to liver injury. World J Hepatol 2021; 13(10): 1367-1377 [PMID: 34786172 DOI: 10.4254/wjh.v13.i10.1367] [Reference Citation Analysis]
3 Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep 2020;10:21742. [PMID: 33303924 DOI: 10.1038/s41598-020-78840-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2016;46:E194-E200. [PMID: 26123753 DOI: 10.1111/hepr.12547] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
6 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
7 Ignatiev E, Samardzija MK, Paul S, Vuckovic KM, Lockwood MB. Standardized Patient Education for Decompensated Cirrhotic Patients and Impact on Clinician Satisfaction. Gastroenterol Nurs 2021;44:233-9. [PMID: 34176889 DOI: 10.1097/SGA.0000000000000543] [Reference Citation Analysis]
8 Gaspar R, Rodrigues S, Silva M, Costa-Moreira P, Morais R, Andrade P, Cardoso H, Albuquerque A, Liberal R, Macedo G. Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. Dig Liver Dis 2019;51:1423-9. [PMID: 31113738 DOI: 10.1016/j.dld.2019.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
9 Dai J, Zhao J, Du Y, McNeil EB, Chongsuvivatwong V. Biomarkers and sociodemographic factors predicting one-year readmission among liver cirrhosis patients. Ther Clin Risk Manag 2019;15:979-89. [PMID: 31496713 DOI: 10.2147/TCRM.S203883] [Reference Citation Analysis]
10 Paciej-Gołębiowska P, Pikala M, Maniecka-Bryła I. Years of life lost due to diseases of the digestive system in Poland according to socioeconomic factors: a cross-sectional study. BMJ Open 2019;9:e030304. [PMID: 31462484 DOI: 10.1136/bmjopen-2019-030304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Sanabria JR, Kombu RS, Zhang GF, Sandlers Y, Ai J, Ibarra RA, Abbas R, Goyal K, Brunengraber H. Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma. HPB (Oxford) 2016;18:979-90. [PMID: 28340971 DOI: 10.1016/j.hpb.2016.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, Shaw SY. The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS One. 2017;12:e0186301. [PMID: 29069090 DOI: 10.1371/journal.pone.0186301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]